Cargando…

SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines

Certain aspects of the immunogenicity and effectiveness of the messenger ribonucleic acid (mRNA) vaccines (mRNA-1273 and BNT162b2) developed in response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are still uncharacterized. Serum or plasma samples from healthy donor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hickey, Thomas E., Kemp, Troy J., Bullock, Jimmie, Bouk, Aaron, Metz, Jordan, Neish, Abigail, Cherry, James, Lowy, Douglas R., Pinto, Ligia A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Coronavirus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305493/ https://www.ncbi.nlm.nih.gov/pubmed/37264688 http://dx.doi.org/10.1080/21645515.2023.2215677

Ejemplares similares

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021
por: Fortunato, Francesca, et al.
Publicado: (2023)

Medium-term outcomes of myocarditis and pericarditis following BNT162b2 vaccination among adolescents in Hong Kong
por: Chua, Gilbert T., et al.
Publicado: (2022)

COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia
por: Yang, Su Lan, et al.
Publicado: (2022)

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines
por: Kyaw, Moe H., et al.
Publicado: (2023)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Author’s reply to correspondence
por: Ripabelli, Giancarlo, et al.
Publicado: (2023)

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection
por: Suah, Jing Lian, et al.
Publicado: (2022)

Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in adolescents aged 12–17 years: A systematic review and meta-analysis
por: Katoto, Patrick DMC., et al.
Publicado: (2023)

Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case–control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2022)

Effectiveness of BNT162b2 and CoronaVac vaccines in preventing SARS-CoV-2 Omicron infections, hospitalizations, and severe complications in the pediatric population in Hong Kong: a case-control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2023)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study
por: Lai, Francisco Tsz Tsun, et al.
Publicado: (2022)

Reduced neutralization of SARS-CoV-2 Omicron variant by BNT162b2 vaccinees’ sera: a preliminary evaluation
por: Mileto, D., et al.
Publicado: (2022)

Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan
por: Naito, Toshio, et al.
Publicado: (2021)

Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients
por: Higashimoto, Yuki, et al.
Publicado: (2022)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Covid-19 vaccines elicit effective IgG responses in an elderly thymus cancer patient with chemotherapy
por: Koller, Akos, et al.
Publicado: (2023)

Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects
por: Borgonovo, Fabio, et al.
Publicado: (2022)

Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case–control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2023)

Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans
por: Dickerman, Barbra A., et al.
Publicado: (2021)

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
por: Thompson, Mark G., et al.
Publicado: (2021)

Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12–17 years: A systematic review and meta-analysis
por: Katoto, Patrick D. M. C., et al.
Publicado: (2022)

Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination
por: Iketani, Sho, et al.
Publicado: (2021)

Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines
por: Montoya, José G., et al.
Publicado: (2021)

Cellular and Humoral Responses in Dialysis Patients after Vaccination with the BNT162b2 or mRNA-1273 Vaccines
por: Mavrovouniotis, Ilias, et al.
Publicado: (2023)

The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273
por: Markewitz, Robert, et al.
Publicado: (2022)

Immunogenicity and safety of BNT162b2 mRNA COVID-19 vaccine in a subject affected by Shapiro’s syndrome: A case report
por: Moscara, Lorenza, et al.
Publicado: (2022)

Does ChAdOx1-S and BNT162b2 heterologous prime-boost vaccination trigger higher rates of vaccine-related adverse events?
por: Haji, Alhan, et al.
Publicado: (2023)

Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination
por: Goddard, Kristin, et al.
Publicado: (2022)

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults
por: Niyomnaitham, Suvimol, et al.
Publicado: (2022)

Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine
por: Islam, Nazmul, et al.
Publicado: (2022)

Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection
por: Keshavarz, Behnam, et al.
Publicado: (2022)

Trajectory of COVID-19 vaccine hesitancy post-vaccination and public’s intention to take booster vaccines: A cross-sectional analysis
por: Salman, Muhammad, et al.
Publicado: (2023)

BNT162b2, mRNA-1273 : des vaccins mis en examen à l’EMA
por: Manus, Jean-Marie
Publicado: (2021)

Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
por: Kitagawa, Hiroki, et al.
Publicado: (2022)

Correlates of uptake of COVID-19 vaccines and motivation to vaccinate among Malawian adults
por: Whitehead, Hannah S., et al.
Publicado: (2023)

SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response
por: Mileto, D., et al.
Publicado: (2021)

COVID-19 mass vaccination – an illustration of the impact of syringe choice on the effectiveness of mass vaccination campaigns
por: Mazet, Roseline, et al.
Publicado: (2022)

Tracking trends in COVID-19 vaccines based on 47 different vaccines: A bibliometric review
por: Tao, Zhongbin, et al.
Publicado: (2023)

Comparison of Kinetics of Antibody Avidity and IgG Subclasses’ Response in Patients with COVID-19 and Healthy Individuals Vaccinated with the BNT162B2 (Comirnaty, Pfizer/BioNTech) mRNA Vaccine
por: Rastawicki, Waldemar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_arai0m52u9d773ce90q7np04ik